Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
OTU deubiquitinase 1 (OTUD1) is a member of the OTU (ovarian tumor) family of cysteine proteases classified as a deubiquitinating enzyme (DUB). It specifically hydrolyzes K63-linked polyubiquitin chains, thereby regulating various signaling pathways including canonical NF-κB activation, interferon antiviral responses, apoptosis, necroptosis, and antioxidant mechanisms via KEAP1 binding. OTUD1's biological roles extend to ribosome quality control by deubiquitinating ribosomal protein RPS10/eS10, influencing mRNA stability and translation in cells, and enhancing iron transport through stabilization of IREB2. Aberrant OTUD1 function or expression is linked to cancer aggressiveness, inflammatory conditions, and neurodegenerative disease. While no drugs currently target OTUD1, it represents a promising therapeutic target due to its central role in controlling inflammation, cell death, and proteostasis
Drugs (if developed) would likely inhibit or modulate OTUD1's deubiquitinating activity, affecting K63-linked ubiquitin chain hydrolysis, NF-κB signaling, and downstream apoptotic or inflammatory processes
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on OTU deubiquitinase 1 (OTUD1).